Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will participate in the virtual H.C Wainwright @ Home fireside chat series taking place on Tuesday, December 3, 2024 at 11:00 am ET.
华明斯特,宾夕法尼亚州,2024年11月26日(全球新闻通讯) -- 阿尔布图斯生物制药公司(纳斯达克:ABUS)(“阿尔布图斯”或“公司”)是一家临床阶段的生物制药公司,利用其广泛的病毒学专业知识,开发针对慢性乙型肝炎病毒(cHBV)感染的功能性治愈方案。今天公司宣布,将参加2024年12月3日东部时间上午11:00举行的虚拟H.C. Wainwright @ Home炉边聊天系列。
To access the live webcast of the fireside chat, please visit: . An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.
要访问炉边聊天的现场直播网络广播,请访问:。活动结束后,阿尔布图斯网站将提供网络广播的归档回放,限时可用。
About Arbutus
关于越桔公司
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Arbutus believes the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Arbutus' pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has achieved meaningful functional cure rates in patients with cHBV when administered as combination therapy. Plans are underway to advance imdusiran into a Phase 2b clinical trial. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit .
阿尔布图斯生物制药公司(纳斯达克:ABUS)是一家临床阶段的生物制药公司,利用其广泛的病毒学专业知识开发具有不同作用机制的新型治疗药物,这些药物可能结合起来,为慢性乙型肝炎病毒(cHBV)患者提供功能性治愈。阿尔布图斯认为,开发功能性治愈的成功关键在于抑制HBV DNA、减少表面抗原以及增强HBV特异性免疫反应。阿尔布图斯内部开发的专有化合物管线包括RNA干扰治疗药物imdusiran(Ab-729)和口服PD-L1抑制剂Ab-101。在联合疗法下,Imdusiran在cHBV患者中已实现有意义的功能性治愈率。目前计划将Imdusiran推进至20亿临床试验。Ab-101目前正在进行1a/10亿临床试验的评估。欲了解更多信息,请访问。
Contact Information
联系信息
Investors and Media
投资者和媒体
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
Lisa M. Caperelli
投资者关系副总裁
电话:215-206-1822
电子邮件:lcaperelli@arbutusbio.com